Creative Planning reports 14.37% increase in ownership of 2B30 / Xeris Biopharma Holdings, Inc.

Xeris 生物製藥控股公司

DE ˙ DB ˙ US98422E1038

€5.20 ↑0.22 (4.40%)

2026-06-05
分享價格

Security	DE:2B30 / Xeris Biopharma Holdings, Inc.
Institution	Creative Planning
Latest Disclosed Ownership	133,285 shares
Latest Disclosed Value	$ 773,053

On May 12, 2026 - Creative Planning filed a 13F-HR form disclosing ownership of 133,285 shares of Xeris Biopharma Holdings, Inc. (DE:2B30) valued at $642,700 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 116,538 shares of Xeris Biopharma Holdings, Inc.. This represents a change in shares of 14.37% during the quarter. The current value of the position is $693,082 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-12	2026-03-31	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	133,285	16,747	14.37	773	-15.43	0.0005
2026-02-17	2025-12-31	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	116,538	-10,442	-8.22	915	-11.52	0.0007
2025-11-14	2025-09-30	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	126,980	9,225	7.83	1,034	88.16	0.0008
2025-08-08	2025-06-30	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	117,755	11,023	10.33	550	-6.15	0.0005
2025-05-15	2025-03-31	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	106,732	15,465	16.94	586	89.32	0.0006
2025-02-14	2024-12-31	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	91,267	47,088	106.58	309	147.20	0.0003
2024-10-11	2024-09-30	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	44,179	-1,623	-3.54	126	21.36	0.0001
2024-08-15	2024-06-30	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	45,802	16,607	56.88	103	60.94	0.0001
2024-05-13	2024-03-31	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	29,195	29,195		65		0.0001
2023-11-16	2023-09-30	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	0	-11,393	-100.00	0	-100.00
2023-07-21	2023-06-30	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	11,393	11,393		30		0.0000

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.